Gunggung dhuwit awis saben saham aldeyra.com (ALDX)

Aldeyra Therapeutics (ALDX) utilizes a unique aldehyde scavenger technology that enables steroid-free eye treatment, a position supported by the company's cash per share. The value 0.69 serves as the current liquidity parameter. While revenue growth relies on the market launch of reproxalap, potential FDA delays and uncertainty regarding partnerships with pharma behemoths are creating downward pressure on the stock.
Rincian metrik komprehensif lan analitis aldeyra.com (ALDX)

For the US ophthalmology biotech sector, which remains shielded from geopolitical shocks, liquidity reserves serve as a guarantee of operational stability during drug development. The cash per share history reflects the actual volume of cash reserves attributable to a single security, allowing investors to assess the real cash cushion of Aldeyra Therapeutics (ALDX) relative to its market value.